

JULIFLORINE SUSCEPTIBILITY OF ANIMAL AND HUMAN ISOLATES OF CAMPYLOBACTER

Pages with reference to book, From 20 To 24

Aqeel Ahmad, Shahana Urooj Kazmi, Khurshid Ali Khan (Department of Microbiology, University of Karachi, Karachi -32,Pakistan.)

Viqar Uddin Ahmad, Sabiha Qazi (HEJ Institute of Chemistry, University of Karachi, Karachi -32,Pakistan.)

Abstract

Juliflorine, the main alkaloid isolated from *Prosopis juliflora* was tested for its antibacterial activity against both the Gram positive and Gram negative bacteria. Filter paper disks impregnated with juliflorine were placed on streaked agar medium. Zones of growth inhibition for *Campylobacter* spp occurred at 10 µg per disk. Other enteropathogens (including the species of *Salmonella*, *Shigella*, *Vibrio*, *Escherichia*, *Proteus*, *Pseudomonas*, *Klebsiella* and *Yersinia*) were resistant to at least 30 µg per disk, with the exception of a strain of *Aeromonas hydrophila*, which showed some inhibition at 30 µg per disk. Most of the 25 *Campylobacter* strains, which were isolated from human clinical and animal sources, showed zones of inhibition greater than 10mm with 10 µg of juliflorine (JPMA 38: 20 , 1988).

INTRODUCTION

Campylobacter jejuni is now recognized world wide as a major cause of bacterial diarrhea in man. The development of selective plating medium¹ and the use of micro-aerophilic (5% O₂ , 10% CO₂ and 85% N₂) incubation has greatly improved the recovery rates of *C. jejuni* from clinical stool specimens. In general *C. jejuni* enteritis is a self-limiting disease, but sometimes the micro-organism provoke a more severe and prolonged illness. Complications, associated with *C. jejuni* enteritis, include reiter's syndrome², reactive arthritis³ and Guillain Barre syndrome^{4,5}. Seriously ill and septicemic patients have to be treated with appropriate antibiotics. The role of antibacterial agents in the therapy of diarrhea is somewhat controversial⁶ although many of them are accepted as standard treatments. Due to the toxicity and increasing drug resistance among different enteropathogens, chemotherapy for most intestinal infections is very often considered as ineffective and even disadvantageous. An alternative source of therapeutic substances are the medicinal plants. Siddiqui and Murthi⁷ reported in 1948 that aqueous and alcoholic extracts of *Prosopis juliflora*, a shrub that grows abundantly in Sind and Punjab provinces of Pakistan .⁸ have antibacterial activity. The isolation of juliflorine, the main alkaloid of *P. juliflora* was first achieved by Ahmed et al.⁹ In an attempt to study the anti-bacterial activity of juliflorine against 22 distinct bacterial species, we discovered a diagnostic characteristic useful in the presumptive identification of *Campylobacter* spp.

MATERIAL AND METHODS

In vitro juliflorine susceptibility assay:— From a stock solution of juliflorine dihydrochloride (10 mg/ml in sterile distilled water) 20 µl dilution containing 1, 5, 10, 20, 30 and 50 µg of juliflorine were prepared and applied to sterile 6 mm filter paper disks (Schleicher and Schuell, Inc., Keene, N.H.). The disks were dried at room temperature and stored at 4°C until use. One loopful of approximately 10⁶ — 10⁷ CPU (colony forming units) was streaked on to the surface of Mueller Hinton agar (oxid) plates and the disks were aseptically applied and pressed into the agar surface. The plates of *C. jejuni* were incubated at 42°C under a microaerobic atmosphere for 48 hours and zones of inhibition were

measured. Penicillin, streptomycin, erythromycin, ampicillin and tetracycline were also used for comparative studies. Plates streaked with aerobic organisms were incubated at 37°C after applying appropriate disks.

RESULTS

Campylobacter strains were found to be highly susceptible to very low level of juhiflorine. Most of the strains used gave a zone of inhibition of more than 10 mm with the 10 pg disk. A total of 25 strains of *C jejuni*, *C. coli* and *C. lariidis*, three other species of *Campylobacter* and 11 enteric bacteria commonly found in clinical stool samples were screened for juhiflorine susceptibility with impregnated disks. No significant differences were observed between isolates from clinical sources (n=9) and from meat sources (n=6) (Table I).

TABLE I
Zones of Inhibition of Gram Negative Bacteria .

Culture used	Source	Donor	Zones of inhibition in mm	
			Juliflorine	
			30 µg	50 µg
<i>Salmonella Schottmuelleri</i>	Human	a	00	00
<i>Shigella dysenteriae</i>	Human	a	00	00
<i>Shigella sonnei</i>	Human	a	00	10
<i>Proteus vulgaris</i>	Human	a	00	09
<i>Klebsiella oxytoca</i>	Human	a	00	08
<i>Escherichia coli</i>	Human	a	00	10
<i>Pseudomonas aeruginosa</i>	Human	a	00	00
<i>Vibrio cholera</i>	Human	b	00	08
<i>Vibrio parahaemolyticus</i>	Human	b(2)	00	00
<i>Yersinia enterocolitica</i>	Human	c(2)	00	00
<i>Aeromonas hydrophilia</i>	Human	d(2)	11	22
<i>Campylobacter jejuni</i>	Human	e(2), f(11), g(2), h(1), i(1)	28	36
<i>Campylobacter laridis</i>	Human	j(1)	30	35
<i>Campylobacter fetus subsp. intestinalis</i>	Human	f(1)	27	32
<i>Campylobacter jejuni</i>	Chicken	k(8)	22	30
<i>Campylobacter jejuni</i>	Pork	k(3)	25	33
<i>Campylobacter jejuni</i>	Lamb	k(3)	24	29
<i>Campylobacter fetus subsp. fetus</i>	Sheep	f(1)	21	31
<i>Campylobacter fetus subsp. venerealis</i>	Cow	f(1)	21	30

a = K.A. Khan, University of Karachi, Karachi-32, Pakistan.

b = M. Voll, University of Maryland, College Park, MD, U.S.A.

c = T. Cook, University of Maryland, College Park, MD, U.S.A.

d = S. Joseph, University of Maryland, College Park, MD, U.S.A.

e = Navel Medical Research Institute, Bethesda, MD, U.S.A.

f = American type culture collection, Rockville, MD, U.S.A.

g = R. Kazmi, Childrens Hospital, Washington, U.S.A.

h = C. Buchrski, George town University Hospital, Washington, U.S.A.

i = M. Doyle, Food Research Institute, Madison Wisconsin, U.S.A.

j = B.S. Robertson, University of Maryland, College Park, MD, U.S.A.

k = N.J. Stern, Meat Science Research Lab. Bettsville, MD, U.S.A.

The average zones of inhibition were 34 mm and 30.6mm respectively, when the isolates were subjected to 50 pg disk of juliflorine. Non — *C. fe/uni* and Non — *C. coil* were also highly susceptible to 10 pg of juliflorine including *C laridis* which, like others¹⁰ was found resistant to tetracycline and nalidixic acid and, in contrast, all other enteropathogens tested were resistant to more than 30 pg per disk with the exception of one strain of *Aenomonas hydrophiiia* which showed susceptibility at 20 pg disk. Most of the enteric bacteria tolerated 50 pg per disk while some responded slightly (Table 1). When juliflorine susceptibility of *Campy lo-bacter* strains wasP compared with other antibiotics listed in Table II,


TABLE II

Comparison of Antibacterial Activity of Juliflorine with Antibiotics.

Culture used	Conc in μ g	Zones of inhibition in mm					
		Juliflorine	Ampicillin	Erythro- mycin	Penicillin	Streptomy- cin	Tetracycline
Streptococcus pneumoniae	1	10	00	00	00	00	00
	5	12	00	00	00	08	00
	10	15	00	08	00	11	10
	20	17	00	10	10	18	13
	30	21	12	16	14	22	17
Streptococcus viridans	1	00	00	00	00	00	00
	5	00	00	00	00	00	00
	10	00	00	00	00	09	09
	20	08	00	00	08	11	12
	30	10	00	00	13	13	15
Streptococcus lactis	1	09	00	00	00	08	00
	5	12	10	07	10	11	09
	10	16	12	09	13	17	12
	20	18	16	12	17	21	17
	30	24	19	15	21	28	22
Staphylococcus epidermidis	1	00	00	00	00	10	10
	5	11	00	00	10	12	12
	10	15	11	00	13	18	16
	20	22	13	10	15	21	20
	30	27	18	12	20	27	26
Sarcina lutea	1	10	00	08	10	08	10
	5	12	10	10	12	12	13
	10	14	12	13	15	16	18
	20	18	15	15	19	21	23
	30	23	17	20	23	26	27
Bacillus megaterium	1	00	10	00	13	08	09
	5	00	13	07	17	10	15
	10	10	17	10	20	16	18
	20	16	20	17	23	20	20
	30	20	26	20	28	26	24
Campylobacter Jejuni	1	00	00	00	00	00	00
	5	09	00	00	00	00	00
	10	12	00	00	00	12	00
	20	19	00	00	08	17	09
	30	28	00	00	11	28	11

majority of the strains were resistant to erythromycin and ampicillin (30 ug/disk). Tetracycline and penicillin produced some inhibition giving a zone of 12 mm around a disk of 30 ug. C. jejuni were found to be equally susceptible to juliflorine and streptomycin. A 30 ug disk of both the juliflorine and streptomycin produced a 28 mm zone of inhibition. Against Gram positive bacteria, juliflorine was

found to be significantly effective against *Streptococcus pneumoniae*, *S. lactis*, *Staphylococcus epidermidis*, *Sarcina lutea*, *Bacillus megaterium* while *Streptococcus viridans* responded slightly. The effectiveness of juliflorine against *S. lactis*, *S. pneumoniae* and *S. epidermidis* exceeded that of ampicillin, erythromycin, penicillin and tetracycline and matched or slightly less than streptomycin. *S. viridans* was found to be resistant to ampicillin and erythromycin but responded poorly to juliflorine. Penicillin, streptomycin and tetracycline are comparatively more effective. Both juliflorine and penicillin are more effective than ampicillin and erythromycin against *S. lutea* but less effective than streptomycin and tetracycline. Activity of juliflorine against *B. megaterium* was found identical with erythromycin but less than the other antibiotics used. Comparison is also made between *Campylobacter* of man and animal sources and Gram positive and Gram negative bacteria (Figure 1).



— Concentration of Juliflorine in μg —

Figure 1. Comparative Antibacterial activity of Juliflorine.

--- *Campylobacter Jejuni* (Human Source)

— *Campylobacter Jejuni* (Animal source)

Δ Gram positive *Gram Negative Bacteria

DISCUSSION

The antibacterial activity of juliflorine, an alkaloid isolated from a medicinal plant *Prosopis fuliflora* has been tested against 16 Gram negative and 6 Gram positive bacteria *Campylobacter* spp, *Streptococcus lactis*, *S. pneumoniae*, *S. viridans*, *Staphylococcus epidermidis*, *Sarcina lutea* and *Bacillus megaterium* were found to be highly susceptible to the alkaloid in low concentrations (10 µg per disk) as compared to antibiotic used (Table II). Enteritis due to *C. jejuni* is usually a mild disease, self-limiting in most cases. However, antibiotic therapy may be indicated in the severe cases, in patients with prolonged illness. The current drug of choice is probably erythromycin which is known for its low toxicity but the prevalence of resistant strains may be a serious problem. Most of the strains we used in this study were found to be resistant at 30 µg erythromycin per disk and showed some inhibition with same concentration of tetracycline and penicillin (11mm zone/30 µg disk). The inhibitory effect of juliflorine on *Campylobacter* growth is almost identical with streptomycin (28 mm zone / 30 µg disk). Ampicillin, sulfonamide and cotrimaxazole were found to be moderately active against *Campylobacter* spp. The use of tetracycline, chloramphenicol and some other drugs is probably limited because of the risk of serious side effects and their toxicity. Microbial resistance¹¹ due to indiscriminate use of antibiotics is a constant threat to the usefulness of almost any drug. We suggest that juliflorine, a naturally occurring plant alkaloid may be used as therapeutic drug to control chronic *Campylobacter* infections. Since juliflorine, effectively inhibited the growth of Gram positive bacteria it can also be used against infection with these bacteria. However, this new compound as well as other need to undergo carefully controlled clinical trials in order to evaluate their usefulness in daily medical practice. The juliflorine has already been evaluated for carcinogenicity in Ames Salmonella/Microsomal test system and it has been established that a dose of upto 500 µg/plate is nonmutagenic and hence non-carcinogenic¹². Juliflorine susceptibility was found to be a very stable characteristic of *Campylobacter* spp and most of the enteric bacteria that cause diarrhoea or dysentery like infections were highly resistant to this alkaloid (Table 1). The presence of *C. jejuni* in stool or food sample can be arrested by the inhibition of growth around a 10 µg juliflorine disk. Juliflorine susceptibility of *Campylobacter* spp may also prove useful as a diagnostic or differential characteristic between *Campylobacter* spp and other potential enteropathogens.

ACKNOWLEDGEMENT

We are thankful to:-

1. Prof. B.S. Roberson, Department of Microbiology, University of Maryland, U.S.A. for providing material to conduct this work.
2. Mr. M.Khalil Ahmed for technical assistance.

REFERENCES

1. Skirrow, M.B. *Campylobacter* enteritis; a 'new' disease. *Br. Med. J.*,1977;2:9.
2. Johnsen, K., Ostensen, M., Melby, A.C. and Melby, K. HLA-B27 negative arthritis related to *Campylobacter jejuni* enteritis in three children and two adults. *Acta Med. Scand.*, 1983; 214:165.
3. Ebricht, J.R. and Ryay, L.M. Acute erosive reactive arthritis associated with *Campylobacter jejuni* induced colitis. *Am. J. Med.*, 1984; 76:321.
4. Kaldor, J. and Speed, B.R. Guillain-Barre syndrome and *Campylobacter jejuni*: a serological study. *Br. Med. J.*, 1984 ;288:1867.
5. Rhodes, K.M. and Tattersfield, A.E. Guillain-Barre syndrome associated with *Campylobacter*

infection. Br. Med. J., 1982; 285: 173.

6. Michael, G. Diarrhoeal disease and malnutrition. A clinical update. Edinburgh, Churchill Livingstone, 1985, p.128.

7. Siddiqui, S. and Murthi, S. Antibiotic activity of leaf extracts of *F. juliflora*, J. Sd. Ind. Res., 1984; 71 : 188.

8. Nasir, E., and Ali, S.I. Flora of West Pakistan, 383 Fakhri Karachi Printing Press, 1972.

9. Ahmad, V.U. and Mohammad, Z.G. Studies on structure of juliflorine. J. Chem. Soc. Pak., 1979; 1: 137.

10. Benjamin, J., Leaper, S., Owen, R.J. and Skirrow, M.B. Description of *Campylobacter laridis*, a new species comprising the nalidixic acid and resistant thermophilic *Campylobacter* (NARTC) group. C. Microbiol., 1983; 8 : 231.

11. Sydney, S., Lacey, R.W. and Bakhtiar, M. The Beta-lactam Antibiotics penicillin and cephalosporin in perspective. London, Hodder and Stoughton, 1980, p.224.

12. Khursheed, A.K., Arshad, H.F., Viquaruddin, A., Sabiha, Q., Sheikh, A.R. and Tahir, T.S. In vitro studies of antidermatophytic activity of juliflorine and its screening as carcinogen in *Salmonella* /Microsome Test System. Arzchim-Forschung (Drug Res)., 1986; 17-19.